Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion surgery rate remain suboptimal. Irreversible electroporation (IRE) is a non-thermal ablation technique that can induce tumor cell death while preserving surrounding vascular and biliary structures. Emerging evidence suggests that IRE may enhance anti-tumor immunity and synergize with systemic therapy. This prospective, single-center, open-label study aims to evaluate the ef

Trial Details

NCT ID

NCT07832006

Phase

PHASE2

Sponsor

Shunda Du

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Irreversible Electroporation
Lenvatinib
Sintilimab

Locations (sample)

Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China, China|39.9075,116.39723

Key Eligibility Criteria

Age 18 to 75 years.
Clinically or pathologically confirmed hepatocellular carcinoma (HCC).
Unresectable HCC corresponding to CNLC stage IIa, IIb, or IIIa, without extrahepatic metastasis.
At least one measurable lesion according to RECIST version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →